New product offerings extend bunion market leadership and accelerate penetration into new foot & ankle market adjacencies

PONTE VEDRA, Fla., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and other foot & ankle conditions, today announced it will highlight multiple new product innovations and present clinical data at the American Orthopaedic Foot & Ankle Society (“AOFAS”) Annual Meeting in Seattle, Washington from September 16-19, 2026.

"We are excited to showcase our expanding portfolio of best-in-class foot & ankle innovations at AOFAS 2026," said John T. Treace, CEO, Founder and Chairman of Treace. “This year, we will be featuring several new technologies aimed at advancing our leadership in the bunion market, while also extending our reach into the mid and hindfoot market which allows us to more comprehensively service our surgeon customers’ needs.”

Technologies to be featured in surgeon training events and at Treace’s AOFAS exhibit booth:

Latest Advancements to Treace’s Market-Leading 3D Bunion Correction Portfolio

Lapiplasty® Lightning™ System: Featuring next-generation instrumentation to accompany the SpeedTMT® implant technology, designed to provide surgeons with ultimate control of their 3D bunion correction, while reducing surgical steps for a faster procedure.
Tailorplasty™ MIS Tailor’s Bunion System: A minimally invasive solution for the surgical treatment of tailor’s bunions, or “bunionettes”, which are painful deformities of the 5^th metatarsal estimated to affect approximately 5-10% of the adult population.
Treace™ X-ray App: Cloud-based software for making radiographic measurements in foot and ankle X-rays, putting anatomical measurements at the fingertips of surgeons.

New Innovations Expanding Treace’s Reach into the Mid and Hindfoot Markets

SuperBite™ Fully-Threaded Compression Screws: Comprehensive system of self-drilling screws designed to reduce steps and save time in fusion and osteotomy procedures, addressing a broad range of foot & ankle applications across the forefoot, midfoot, and hindfoot.
HyperPlate™ XM Dynamic Compression Locking Implant: Advanced fixation construct combining locking screws and dynamic compression for a highly stable construct with an anatomic shape designed to promote fusion in the larger bones of the midfoot and hindfoot.
CartiBlaster™ Powered Joint Prep instruments: Sterile, single-use instruments designed for fast and controlled cartilage removal and joint preparation in fusion procedures throughout the midfoot and hindfoot.
VitaFuse™ Bioactive Glass Graft: A new synthetic bone graft technology that expands our growing biologics portfolio, which includes our tissue-based CortiFuse™ graft and procedure specific wedges.

Results highlighting the clinical performance of Treace technologies in the landmark 5-year ALIGN3D® Lapiplasty®, MTA3D™ Adductoplasty® and SPRINT™ SpeedPlate® studies will be presented during the AOFAS Annual Meeting.

Clinical Data Presentation Schedule

Friday, September 18 at 8:45am PST: The ALIGN3D® Lapiplasty® clinical study podium presentation, “Five-Year Analysis of a Prospective Multicenter Study of Triplanar Tarsometatarsal Arthrodesis With Early Weightbearing: Radiographic, Clinical and Patient Reported Outcomes”, will be presented by Daniel Farber, MD, Lehigh Valley Orthopedic Institute (Bethlehem, PA).
Thursday, September 17 at 4:00pm PST: The MTA3D® Adductoplasty® clinical study podium presentation, “Radiographic and Patient-Reported Outcomes Following Combined Metatarsus Adductus and Hallux Valgus Correction with Early Weightbearing – 2-year Interim results of a Multicenter Prospective Study”, will be presented by Mark Easley, MD, Duke University (Durham, NC).
Audio poster presentation: The SPRINT™ SpeedPlate® observational clinical study, “Radiographic and Patient-Reported Outcomes Following Joint Arthrodesis in the Foot Using a Novel, Dynamic Compression Implant System”, will be presented by Jody McAleer, DPM, Jefferson City Medical Group (Jefferson City, MO).

About Treace Medical Concepts

Treace Medical Concepts, Inc. is a medical technology company with the goal of being the recognized leader in the surgical treatment of bunions and other foot & ankle conditions. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty^®3D Bunion Correction^® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of surgeons and bunion patients, Treace offers its Adductoplasty^® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, two systems for minimally invasive osteotomy procedures, namely the Nanoplasty^® 3D Minimally Invasive Bunion Correction System and the Percuplasty^® Percutaneous 3D Bunion Correction System, and the SpeedMTP^® 1^st MTP Fusion System. Treace continues to expand its footprint in the marketplace by extending its SpeedPlate^® rapid compression implant platform to new applications, providing surgeons with advanced digital solutions with its IntelliGuide^® patient specific, pre-op planning and cut guide technology, and offering SuperBite™ Fully-Threaded Compression Screws for use in fusions throughout the foot. For more information, please visit www.treace.com.

To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.

Contacts:

Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940

Investors:
Gilmartin Group
Philip Trip Taylor
IR@treace.net

Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting